Cargando…

Immune and inflammation: related factor alterations as biomarkers for predicting prognosis and responsiveness to PD-1 monoclonal antibodies in cervical cancer

PURPOSE: We aimed to elucidate the potential mechanisms of effective responsiveness to PD-1 monoclonal antibody and evaluate more reliable biomarkers to improve the ability to predict the populations of cervical cancer (CC) suitable for immunotherapy. METHODS: Peripheral blood samples of CC patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xihan, Zhang, Xi, Liu, Chang, Mu, Wendi, Peng, Jin, Song, Kun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9519820/
https://www.ncbi.nlm.nih.gov/pubmed/36171464
http://dx.doi.org/10.1007/s12672-022-00560-8
_version_ 1784799484274802688
author Liu, Xihan
Zhang, Xi
Liu, Chang
Mu, Wendi
Peng, Jin
Song, Kun
author_facet Liu, Xihan
Zhang, Xi
Liu, Chang
Mu, Wendi
Peng, Jin
Song, Kun
author_sort Liu, Xihan
collection PubMed
description PURPOSE: We aimed to elucidate the potential mechanisms of effective responsiveness to PD-1 monoclonal antibody and evaluate more reliable biomarkers to improve the ability to predict the populations of cervical cancer (CC) suitable for immunotherapy. METHODS: Peripheral blood samples of CC patients undergoing anti-PD-1 therapy were collected before and after treatment. Differentially expressed genes (DEGs) were analyzed between partial response (PR) and progressive disease (PD) patients. A novel prognostic inflammation and immune–related response gene (IRRG) model was constructed and its prognostic role, correlation with tumor immunity and tumor mutation were evaluated. RESULTS: DEGs in PR patient after treatment could predict the response to PD-1 monoclonal antibodies. Among PR-specific pathways, tumor immunity, leukocyte migration, and cytokine activities were prominently enriched. Additionally, an IRRG signature comprising CTLA4, AZU1, C5, LAT, CXCL2, GDF7, MPL, PPARG and CELA1 was established and validated to predict the prognosis of CC with great accuracy and specificity. This signature could reflect the tumor microenvironment (TME) and tumor mutational burden (TMB). We also found stimulated adaptive immunity and downregulated inflammation at baseline in patients with sensitive responses to PD-1 monoclonal antibody. CONCLUSION: We developed an IRRG signature and verified that it was an independent prognostic factor for predicting survival and could reflect a sensitive response to PD-1 monoclonal antibody, which plays a nonnegligible role in the TME of CC. Further investigations are warranted to confirm that patients with stimulated adaptive immunity and downregulated inflammation at baseline could achieve a better survival benefit from PD-1 monoclonal antibody. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12672-022-00560-8.
format Online
Article
Text
id pubmed-9519820
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-95198202022-09-30 Immune and inflammation: related factor alterations as biomarkers for predicting prognosis and responsiveness to PD-1 monoclonal antibodies in cervical cancer Liu, Xihan Zhang, Xi Liu, Chang Mu, Wendi Peng, Jin Song, Kun Discov Oncol Research PURPOSE: We aimed to elucidate the potential mechanisms of effective responsiveness to PD-1 monoclonal antibody and evaluate more reliable biomarkers to improve the ability to predict the populations of cervical cancer (CC) suitable for immunotherapy. METHODS: Peripheral blood samples of CC patients undergoing anti-PD-1 therapy were collected before and after treatment. Differentially expressed genes (DEGs) were analyzed between partial response (PR) and progressive disease (PD) patients. A novel prognostic inflammation and immune–related response gene (IRRG) model was constructed and its prognostic role, correlation with tumor immunity and tumor mutation were evaluated. RESULTS: DEGs in PR patient after treatment could predict the response to PD-1 monoclonal antibodies. Among PR-specific pathways, tumor immunity, leukocyte migration, and cytokine activities were prominently enriched. Additionally, an IRRG signature comprising CTLA4, AZU1, C5, LAT, CXCL2, GDF7, MPL, PPARG and CELA1 was established and validated to predict the prognosis of CC with great accuracy and specificity. This signature could reflect the tumor microenvironment (TME) and tumor mutational burden (TMB). We also found stimulated adaptive immunity and downregulated inflammation at baseline in patients with sensitive responses to PD-1 monoclonal antibody. CONCLUSION: We developed an IRRG signature and verified that it was an independent prognostic factor for predicting survival and could reflect a sensitive response to PD-1 monoclonal antibody, which plays a nonnegligible role in the TME of CC. Further investigations are warranted to confirm that patients with stimulated adaptive immunity and downregulated inflammation at baseline could achieve a better survival benefit from PD-1 monoclonal antibody. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12672-022-00560-8. Springer US 2022-09-28 /pmc/articles/PMC9519820/ /pubmed/36171464 http://dx.doi.org/10.1007/s12672-022-00560-8 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research
Liu, Xihan
Zhang, Xi
Liu, Chang
Mu, Wendi
Peng, Jin
Song, Kun
Immune and inflammation: related factor alterations as biomarkers for predicting prognosis and responsiveness to PD-1 monoclonal antibodies in cervical cancer
title Immune and inflammation: related factor alterations as biomarkers for predicting prognosis and responsiveness to PD-1 monoclonal antibodies in cervical cancer
title_full Immune and inflammation: related factor alterations as biomarkers for predicting prognosis and responsiveness to PD-1 monoclonal antibodies in cervical cancer
title_fullStr Immune and inflammation: related factor alterations as biomarkers for predicting prognosis and responsiveness to PD-1 monoclonal antibodies in cervical cancer
title_full_unstemmed Immune and inflammation: related factor alterations as biomarkers for predicting prognosis and responsiveness to PD-1 monoclonal antibodies in cervical cancer
title_short Immune and inflammation: related factor alterations as biomarkers for predicting prognosis and responsiveness to PD-1 monoclonal antibodies in cervical cancer
title_sort immune and inflammation: related factor alterations as biomarkers for predicting prognosis and responsiveness to pd-1 monoclonal antibodies in cervical cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9519820/
https://www.ncbi.nlm.nih.gov/pubmed/36171464
http://dx.doi.org/10.1007/s12672-022-00560-8
work_keys_str_mv AT liuxihan immuneandinflammationrelatedfactoralterationsasbiomarkersforpredictingprognosisandresponsivenesstopd1monoclonalantibodiesincervicalcancer
AT zhangxi immuneandinflammationrelatedfactoralterationsasbiomarkersforpredictingprognosisandresponsivenesstopd1monoclonalantibodiesincervicalcancer
AT liuchang immuneandinflammationrelatedfactoralterationsasbiomarkersforpredictingprognosisandresponsivenesstopd1monoclonalantibodiesincervicalcancer
AT muwendi immuneandinflammationrelatedfactoralterationsasbiomarkersforpredictingprognosisandresponsivenesstopd1monoclonalantibodiesincervicalcancer
AT pengjin immuneandinflammationrelatedfactoralterationsasbiomarkersforpredictingprognosisandresponsivenesstopd1monoclonalantibodiesincervicalcancer
AT songkun immuneandinflammationrelatedfactoralterationsasbiomarkersforpredictingprognosisandresponsivenesstopd1monoclonalantibodiesincervicalcancer